Brivanib alaninate - ZAI Lab

Drug Profile

Brivanib alaninate - ZAI Lab

Alternative Names: BMS-540215; BMS-582664; Brivanib; ZL-2301

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Gynecologic Oncology Group; National Cancer Institute (USA); ZAI Lab
  • Class Antineoplastics; Esters; Indoles; Pyrroles; Small molecules; Triazines
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • No development reported Solid tumours
  • Discontinued Cervical cancer; Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 26 Sep 2018 Additional efficacy data from a phase II trial in Hepatocellular carcinoma released by Zai Lab
  • 26 Sep 2018 Zai Lab plans a trial for Hepatocellular carcinoma (Combination therapy) in China
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top